EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis

Jason Wen, Suhail Dohad, Richard Shlofmitz, Jeffrey Moses, William Bachinsky, Steven Rudick, Robert Stoler, Brian K Jefferson, William Nicholson, John Altman, Saroj Neupane, Kevin Croce und 7 weitere

JACC: Cardiovascular Interventions · 2025

DOI: 10.1016/j.jcin.2025.09.032 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Jason Wen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Cardiac Catheters, Cardiovascular Agents, Coated Materials, Biocompatible. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Boston Scientific Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment of small vessel (SV) coronary artery disease is associated with higher restenosis rates. Drug-coated balloons offer a promising treatment option for stent failure by delivering an antiproliferative drug and avoiding an additional metal implant. However, evidence supporting the use of paclitaxel-coated balloons (PCBs) for in-stent restenosis (ISR) in SVs is limited. OBJECTIVES: The aim of this study was to evaluate the efficacy and safety of PCB vs uncoated balloon angioplasty according to vessel size. METHODS: AGENT IDE (A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis) randomized 600 patients with ISR to treatment with PCBs or uncoated balloons (2:1). This prespecified analysis evaluated the treatment effect of PCBs in SV (reference vessel diameter [RVD] ≤2.75 mm) and large vessel (RVD >2.75 mm) ISR. The primary endpoint of 1-year target lesion failure (TLF) was a composite of target lesion revascularization, cardiac death, and target vessel-related myocardial infarction. RESULTS: Among 597 patients with known angiographic core laboratory-adjudicated vessel size, 56% had SVs (mean RVD 2.4 ± 0.3 mm) and 44% had large vessels (mean RVD 3.1 ± 0.3 mm). One-year TLF was 20.6% vs 22.6% in the SV vs large vessel groups, respectively (HR: 0.92; 95% CI: 0.65-1.31; P = 0.65). PCBs were associated with a 39% relative reduction in TLF compared with balloon angioplasty in patients with SVs (17.7% vs 27.4%; HR: 0.61; 95% CI: 0.37-0.99) and a 43% reduction in patients with large vessels (18.4% vs 30.5%; HR: 0.57; 95% CI: 0.34-0.96). The benefits of PCB use remained consistent, irrespective of vessel size (Pinteraction = 0.88). None of the patients treated with PCBs experienced definite or probable stent thrombosis. CONCLUSIONS: This prespecified subgroup analysis demonstrates that angioplasty with a PCB was associated with consistently reduced rates of 1-year TLF compared with an uncoated balloon in both SV and large vessel ISR patients. (A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis [AGENT IDE]; NCT04647253).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioplasty, Balloon, CoronaryCardiac CathetersCardiovascular AgentsCoated Materials, BiocompatibleCoronary Artery DiseaseCoronary RestenosisPaclitaxelPercutaneous Coronary InterventionStentsAgedFemaleHumansMaleMiddle AgedCoronary AngiographyEquipment DesignKaplan-Meier EstimateMyocardial InfarctionRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

drug-coated balloonin-stent restenosissmall vesseltarget lesion failuretarget lesion revascularizationuncoated balloon

Substanzen

Cardiovascular AgentsCoated Materials, BiocompatiblePaclitaxel

Autor:innen und Institutionen

  • Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: suhail.dohad@cshs.org.
  • St. Francis Hospital, Roslyn, New York, USA.
  • St. Francis Hospital, Roslyn, New York, USA; Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA.
  • University of Pittsburgh Medical Center, Central Pennsylvania, Harrisburg, Pennsylvania, USA.
  • Lindner Center for Research and Education at Christ Hospital, Cincinnati, Ohio, USA.

Förderung

  • Boston Scientific Corporation

Zitieren

APA

Wen, J., Dohad, S., Shlofmitz, R., Moses, J., Bachinsky, W., Rudick, S., Stoler, R., Jefferson, B. K., Nicholson, W., Altman, J., Neupane, S., Croce, K., Shunk, K., Taylor, A., Saybolt, M. D., Diaz, C., Cavalcante, R., Yeh, R. W., & Kirtane, A. J. (2025). Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.09.032

Vancouver

Wen J, Dohad S, Shlofmitz R, Moses J, Bachinsky W, Rudick S, et al. Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.09.032

BibTeX
@article{Wen2025,
  author = {Wen, Jason and Dohad, Suhail and Shlofmitz, Richard and Moses, Jeffrey and Bachinsky, William and Rudick, Steven and Stoler, Robert and Jefferson, Brian K and Nicholson, William and Altman, John and Neupane, Saroj and Croce, Kevin and Shunk, Kendrick and Taylor, Angela and Saybolt, Matthew D and Diaz, Claro and Cavalcante, Rafael and Yeh, Robert W and Kirtane, Ajay J},
  title = {Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  doi = {10.1016/j.jcin.2025.09.032}
}
Kostenlos starten →